PHIO PHARMACEUTICALS CORP

PHIONASDAQ

🏆 #4926 by market capEarnings Nov 11US Equity

$486.59▼ $2.82 (−0.58%)

Simulated price

🔔

Track PHIO

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.6%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$12M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

No chart data available for PHIO.

Trading Snapshot

Day Range: $478.99 – $490.69
52-Week Range: $0.81 – $4.19
Volume: $2.48B
Avg Volume: $2.89B
Shares Outstanding: 11.6M
Next Earnings: Dec 16, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $560,724
P/E Ratio: -0.8
P/S Ratio: 0.0x
EPS (TTM): $-1.11
Dividend Yield: 0.00%
Dilution (1yr): +1375.3%

Why Investors Own PHIO

✓High-growth profile — revenue up +10.0% YoY with expanding US Equity exposure.
✓Healthy economics — 58% gross margin and 28% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PHIO PHARMACEUTICALS CORP

PHIO

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$9M▲ +24.8% YoY

Free Cash Flow

−$8M▲ +12.3% YoY

Shares Outstanding

11.6M▲ +1375.3% YoY

Net Cash

$21M▲ +$16M YoY

StockOtter · stockotter.space

About PHIO PHARMACEUTICALS CORP

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

🦦